Stockreport

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains [Seeking Alpha]

Oric Pharmaceuticals, Inc.  (ORIC) 
PDF ORIC-944, for the treatment of metastatic prostate cancer, is expected to initiate a combination study in the first half of 2024 and provide a program update in mid-202 [Read more]